HRS-5965 Capsules
Sponsors
Chengdu Suncadia Medicine Co., Ltd.
Conditions
Complement Mediated Glomerular DiseasesComplement Mediated Primary or Secondary Glomerular DiseasesHemolytic AnemiaIgA NephropathyParoxysmal Nocturnal HemoglobinuriaPrimary IgA Nephropathy
Phase 1
Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment
CompletedNCT06674915
Start: 2024-11-26End: 2026-01-16Updated: 2026-01-30
A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects
CompletedNCT07035665
Start: 2025-06-30End: 2025-07-22Updated: 2025-08-20
Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects
CompletedNCT07040787
Start: 2025-07-08End: 2025-08-17Updated: 2025-08-20
Phase 2
Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Active, not recruitingNCT06238544
Start: 2024-02-06End: 2027-12-31Updated: 2025-12-24
A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
RecruitingNCT07582133
Start: 2026-07-06End: 2029-11-01Target: 380Updated: 2026-07-22